Human Vaspin RIA

Human Vaspin RIA

The discovery of leptin in 1994 set in motion an increased interest in the biology of white adipose tissue. Following that, the identification of the products of the obese gene better clarified the role of adipose tissue in the pathobiology of obesity-related diseases, and led to the identification of many other Adipocyte-secreted molecules. Studies have demonstrated that adipokines derived from white-adipose tissue play a role in the metabolic events that lead to metabolic syndrome and inflammatory and autoimmune diseases. One of these adipokines, vaspin (visceral adipose tissue-derived serine protease inhibitor) was found to have insulin-sensitizing effects targeted toward white adipose tissue in states of obesity and a potential role in exerting protective effects by inhibiting adipokine degradation. Visceral vaspin expression has also been demonstrated to significantly correlate with BMI, percent body fat, and two-hour oral glucose tolerance test plasma glucose.

Radioimmunoassay

Two-day disequilibrium assay, incubate at 4°C
Sample volume: 100 µL serum, plasma, or tissue culture sample

Human

• Adipokine Kits
• Radioimmunoassays (RIA)

• Obesity
• Metabolic Disorders

100 – 116%

¹²⁵I-Adiponectin

0.78 ng/mL

• Intra-assay: 3.0 - 6.0%
• Inter-assay: 5.0 - 12%

93 - 101%

¹²⁵I

• SERPINA12
• OL-64

ED₈₀ = 2.15 ± 0.13 ng/mL
ED₅₀ = 7.01 ± 0.42 ng/mL
ED₂₀ = 23.51 ± 1.97 ng/mL

0.78–50 ng/mL

No detectable cross-reactivity of Insulin, C-peptide, Leptin, Glucagon, Adiponectin, or Visfatin